Best Healthcare Companies in Seongnam-si, South Korea
The 50 best Healthcare companies in Seongnam-si, South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Organoid Sciences.
Ranked: Best Healthcare companies in Seongnam-si
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Organoid Sciences Developer of regenerative medicines for multiple diseases | $39M | 54 mo ago | Public | Jongman Yoo CEO | 2019 | WordPressMySQLPHP+22 | — | — |
| 2 | TiumBio Developer of small molecules therapeutics | $32M | 31 mo ago | Public | Kim Hun-Taek CEO | 2016 | PHPGSAPApache HTTP Server+10 | 60 patents Patents concentrated in chemistry & materials | — |
| 3 | PharmaResearch Developer of pharmaceuticals and medical devices based on regenerative medicine | — | 23 mo ago | Late Stage | Kang seok Co-CEO | 1993 | Apple iCloud MailPHPNginx+7 | 37 patents Nucleic‑acid delivery systems and DNA‑based biomaterials for tissue repair. | 1 award |
| 4 | Qurient Developing novel small molecule therapeutics against infectious disease and inflammation | — | 27 mo ago | Public | Kiyean Nam Chief Executive Officer | 2008 | GnuboardMySQLPHP+6 | 178 patents Small-molecule CDK7 inhibitors for oncology, antiviral, and anti-inflammatory therapies | — |
| 5 | OPTOLANE Semiconductor-based molecular diagnostic & immunoassay POC platforms | — | 61 mo ago | Series C | Do Young Lee CEO | 2012 | — | 18 patents Integrated microfluidic biochips for PCR, cell analysis, and fluorescence detection | — |
| 6 | FlexFine Manufacturer of medical devices | — | 85 mo ago | Seed | — | 2014 | — | — | — |
| 7 | Blue M Tech Provider of prescription medicine AI platform for medical supplies and consumables in the healthcare industry | — | 85 mo ago | Public | Hyunsoo Kim Co-CEO | 2015 | PHPNginxGSAP+8 | — | — |
| 8 | Oklight Manufacturer of ophthalmic devices | — | 85 mo ago | Seed | — | 2007 | — | — | — |
Top 12 Healthcare companies in Seongnam-si
#1
Public · Seongnam-si, Gyeonggi-do · founded 2016 · 51 employees$32Mraised▾
TiumBio has developed small molecules and biomolecules for the treatment of cancer, diabetes & rare diseases. The small molecules portfolio includes NCE401 (ALK5 inhibitor for cancer immunotherapy and IPF in preclinical stage), NCE403 (GnRH antagonist for prostate cancer and endometriosis in Phase 1 stage), NCE406 (Type 2 Diabetes mellitus in preclinical stage). Biopharmaceuticals include NBP604 (Recombinant factor VIIa) for hemophilia is in the preclinical stage, NBP611 (hemophilia) and NBP (hemophilia and rare disease) in the discovery stages.
- Jan 2024Post IPO$12M
- Dec 2023Post IPO$29.9M
- May 2018Series B$21.8M
- 2017Series A$10.2M
#2
Public · Seongnam-si, Gyeonggi-do · founded 2019 · 70 employees$39Mraised▾
Organoid Sciences is a developer of regenerative medicines for multiple diseases. It uses cannabinoid-based technology for the development of a regenerative medicine pipeline.
- Jan 2022Series B$32.5M
- Mar 2020Series A$6.4M
#3
Late Stage · Seongnam-si, Gyeonggi-do · founded 1993—raised▾
Developer of pharmaceuticals and medical devices based on regenerative medicine. The organization focuses on creating products aimed at improving human health and well-being. It utilizes proprietary technology to extract and optimize DNA for use in its products. The company exports its products to multiple countries. It also shares company updates through press releases.
#4
Public · Seongnam-si, Gyeonggi-do · founded 2008 · 31 employees—raised▾
Qurient (formerly known as Quro Science) is a spin-off biotechnology company from institute Pasteur Korea (IPK) dedicated to develop novel therapeutics against infectious disease and inflammation. Qurient has exclusive right to use discovery research products (drug candidates) and resources at IPK including the PhenomicScreen. Simultaneously Qurient is searching for In-Licensing opportunities from external partners such as academia and biotech for aligned strategic indications. The company’s pipelines products include Q203 drug for the treatment of Mycobacterium tuberculosis that is in phase I stage; Q301, a drug candidate for the treatment of atopic dermatitis, which is in phase II development stage; and Q501, an orally available 5-lipoxygenase inhibitor for treatment of asthma that is in late stage of lead optimization development stage. Its pipelines products also comprise Q701, a potent and selective TAM kinase-inhibitor for cancer therapy, which is in preclinical development stage; and CDK7 inhibitor that is non-covalent pico molar biochemical inhibitor that is in lead optimization process.
#5
Series C · Seongnam-si, Gyeonggi-do · founded 2012 · 116 employees—raised▾
OPTOLANE Technologies is developing the semiconductor-based POC molecular diagnostics platforms. The company's flagship products are MDx reader systems such as OPTOLANE's PCR, microarray PCR & digital PCR platforms (based on molecular diagnostic processes). Also developing immunoassay based reader platforms & sample preparation devices. All these systems are based on CMOS (complementory metal oxides semiconductors) biosensors.
- 2021Series C—
#6
Seed · Seongnam-si, Gyeonggi-do · founded 2014 · 7 employees—raised▾
Manufacturer of custom scoliosis brace and accessories based in Seongnam-si, South Korea. The company offers custom spinal braces by measuring dimensions remotely and customizing core frames with three-dimensional printing, enabling young patients to treat scoliosis.
- Jun 2019Seed—
#7
Public · Seongnam-si, Gyeonggi-do · founded 2015—raised▾
Provider of prescription medicine AI platform for medical supplies and consumables in the healthcare industry. It also provide services such as online purchasing systems, website development/marketing, and B2B platforms.
- Jun 2019Seed—
#8
Seed · Seongnam-si, Gyeonggi-do · founded 2007 · 4 employees—raised▾
Manufacturer of ophthalmic devices
#9
Seed · Seongnam-si, Gyeonggi-do · founded 2016—raised▾
Provider of wearable smart laser therapy device for the treatment of rhinitis. It offers a medical device that treats allergic rhinitis by using semiconductor laser in the nasal cavity and works by activating the overproduction of reactive oxygen species (ROS) in the blood, which are generated by allergic reactions, and neutralizing them.
- Jun 2019Seed—
#10
Public · Seongnam-si, Gyeonggi-do · founded 2007 · 25 employees—raised▾
Kainos Medicine develops small molecule therapeutics for cancer, neurological and infectious diseases. It currently has drugs for Parkinson's disease in Phase I trials, a HIV anti-infective and three targeted ant-cancer drugs in pre-clinical testing.
#11
Public · Seongnam-si, Gyeonggi-do · founded 2000—raised▾
Clinical stage pharmacy company focused on the novel drugs in areas of inflammation, oncology, and infectious disease
#12
Public · Seongnam-si, Gyeonggi-do · founded 2003—raised▾
Corestem is a company specializing in the development and production of stem cell-based therapies for incurable diseases. The company's only commercialized product Neuronata-R injection is an autologous bone marrow mesenchymal stem cell (autologous BM-MSC) therapy for Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease). The company's other candidates, CS20AT04 (for Lupus) and CS10BR05 (for multiple system atrophy) are in IND stage while their candidate CS30MS02 (for osteoarthritis) is in preclinical stage.
- Aug 2013Series A—
- Dec 2012Series A—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Healthcare coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.